Alzheimer’s disease (AD) is a complex and progressive neurodegenerative
disorder, and represents the most common form of dementia. The number of people
affected by AD is estimated to be doubled by the year of 2050, and more than 100
million people worldwide will be affected by this disease. Still, there is no reliable
diagnostic test which would indicate pre-symptomatic conditions or an increased risk of developing AD. The only drugs
approved by the FDA belong to the cholinesterase inhibitors (ChEI) group, such as donepezil, rivastigmine, galantamine
and memantine that belongs to a class of drugs named receptor NMDA antagonists. Most mainstream pharmacotherapeutic
approaches act by slowing the progression of the condition rather than to treat or prevent the cause of AD. In this review
we are presenting literature data from recent research related to new avenues in the classical approach to prevention
and treatment of AD.
Keywords: Aβ, Alzheimer’s disease, cholinesterase inhibitors, hybrids, memantine, neurodegeneration.
Rights & PermissionsPrintExport